Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport vs Botox in Adult Upper Limb Spasticity: Safety and Efficacy Crossover Trial
2021-000161-32Phase 3Active
- Sponsor
- Ipsen
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in upper extremity spasticity (2 arms), sponsored by Ipsen. Primary endpoint: Rate of treatment-emergent adverse events (TEAEs) from injection to 12 weeks. Started Jun 2021; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
upper extremity spasticity
Beyond the preview
Go deeper on 2021-000161-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000161-32.